The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

Will operators be able to replicate COAPT’s restraint and its outcomes?

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

Three decades after the first Transcatheter Cardiovascular Therapeutics conference, TCT.18’s organizers are moving “toward a more practical approach,” says Cardiovascular Research Foundation CEO Juan Granada, MD.

Patients hospitalized with acute myocardial infarction (AMI) actually fare better when some of the top minds in interventional cardiology are away at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, suggests a study published March 9 in the Journal of the American Heart Association.